Aronora Inc., a Portland biotech startup developing a new kind of blood clot treatment, has inked a deal with Xoma Corp. (NASDAQ: XOMA) for royalty rights related to five drug candidates.
Xoma, a "royalty aggregator" based in Emeryville, Calif., also agreed to acquire a portion of the potential milestone payments associated with the hematology drugs. Three are anti-clotting candidates being developed under a partnership with Bayer, while two have no pharmaceutical partner, according to Xoma’s…
